key: cord-0744938-pju3ajww
authors: Ottaviani, Sébastien; Juge, Pierre-Antoine; Forien, Marine; Ebstein, Esther; Palazzo, Elisabeth; Dieudé, Philippe
title: Polymyalgia rheumatica following COVID-19 vaccination: a case-series of ten patients
date: 2021-12-22
journal: Joint Bone Spine
DOI: 10.1016/j.jbspin.2021.105334
sha: 03ba58bb6f2d255dc9d9dcb5147d59514ba392fa
doc_id: 744938
cord_uid: pju3ajww

nan

Polymyalgia rheumatica (PMR) is a common disease, affecting people over age 50 years. It is characterized by inflammatory pain and stiffness of the shoulders and pelvic girdle. The disease can be associated with giant cell arteritis (GCA). It usually responds to low-dose glucocorticoids (GCs). The pathogenesis remains unclear, but environmental triggers, such as viral infections, are suspected [1] .

PMR was reported after influenzae B infection and more recently after SARS-CoV-2 infection [2] . Regarding the risk of PMR after vaccination, a few cases were reported during the first 3 months after influenzae vaccination [1] . In the context of the COVID-19 pandemic and massive vaccination of the population, the question of the COVID-19 vaccine as a potential trigger can be raised. Here, we report a case-series of ten patients with PMR after COVID-19 vaccination.

The median age of the patients (70% women) was 74.5 years (range 65-89). The clinical and imaging features of all patients are described in Table 1 . Seven patients had new-onset PMR and three had relapsing disease after respectively one, two and 11 years of free-drug remission. All patients fulfilled the 2012 ACR/EULAR criteria for PMR [3] . PMR-mimicking diseases such as rheumatoid arthritis or pyrophosphate calcium disease were ruled out. All patients had inflammatory pain and stiffness of the shoulders and pelvic girdle. The median symptom duration was 10.5 weeks (range 3-24). COVID-19 vaccines were BNT162b2 (shoulders, hips, trochanteric and ischiatic bursitis, symphysis, sternoclavicular joints, interspinous bursitis). The median C-reactive protein level was 26 mg/l (range 3-224). GC therapy was initiated in nine patients and was associated with methotrexate (n=3) or tocilizumab (n=1) and led to an improvement in all. One patient was only treated by local steroid injection.

This case-series highlights that PMR can follow vaccination against COVID-19. This potential link between vaccination and new onset or relapse of PMR/giant cell arteritis was previously described with influenza vaccine [1] . The role of the adjuvant was suspected to induce inflammatory cytokine production such as interleukin-6 or tumor necrosis factor- leading to a flare of the disease [1] . For PMR after COVID-19 vaccination, only few cases were previously reported [4] [5] [6] . Recently, Cadiou et al. reported, after 7 to 14 days after first dose of vaccination, two patients with new onset of PMR and GCA, and one PMR patient relapsing with a final diagnosis of GCA [4] . COVID-19 mRNA vaccines had no adjuvant, but they can themselves stimulate innate immunity with activation of Toll-like receptors (TLRs), notably TLR-7 and TLR-9 [7] . TLR-7 and TLR-9 are overexpressed in mononuclear cells of patients with active PMR [8] , which could explain the occurrence of PMR after mRNA vaccination. As previously reported [1] , the clinical presentation of PMR after vaccination was similar to that without identified triggers. In our case series, the prognosis did not seem to be modified, with good response to the usual therapies. 

Polymyalgia rheumatica following infective triggers or vaccinations: a different subset of disease?

Can SARS-CoV-2 trigger relapse of polymyalgia rheumatica?

provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative

SARS-CoV-2, polymyalgia rheumatica and giant cell arteritis: COVID-19 vaccine shot as a trigger? Comment on: "Can SARS-CoV-2 trigger relapse of polymyalgia rheumatica

Polymyalgia rheumatica as uncommon adverse event following immunization with COVID-19 vaccine: A case report and review of literature

Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination. Vaccines (Basel)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Expression and function of tolllike receptors in peripheral blood mononuclear cells of patients with polymyalgia rheumatica and giant cell arteritis

We thank Laura Smales (BioMedEditing) for copyediting.